▲ +105.81% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Pharvaris B.V. in the last 3 months. The average price target is $47.50, with a high forecast of $51.00 and a low forecast of $41.00. The average price target represents a 105.81% upside from the last price of $23.08.
The current consensus among 4 contributing investment analysts is to buy stock in Pharvaris B.V..
Pharvaris B.V., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.